A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo
A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo
A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI; PT003), FF MDI; PT005, and GP MDI; PT001) in subjects with moderate to very severe COPD, compared with placebo.
A randomized, double-blind, chronic dosing (24 weeks), placebo-controlled, parallel group, multi-center study to assess the efficacy and safety of glycopyrronium and formoterol fumarate inhalation aerosol (GFF; PT003), formoterol fumarate inhalation aerosol (FF; PT005), and glycopyrronium inhalation aerosol (GP; PT001) in subjects with moderate to very severe COPD, compared with placebo.
Inclusion Criteria:
Exclusion Criteria:
Ostrava-Hrabuvka, 700 30, Czechia
Grosshansdof, 22927, Germany
Ako-shi, 678-0239, Japan
Asahikawa-shi, 070-8644, Japan
Himeji-shi, 671-0102, Japan
Himeji-shi, 672-8064, Japan
Itabashi-ku, 173-8610, Japan
Kakogawa-shi, 675-0023, Japan
Kamogawa-shi, 296-0041, Japan
Kishiwada-shi, 596-8501, Japan
Koga-shi, 811-3195, Japan
Matsumoto-shi, 390-0872, Japan
Matsumoto-shi, 390-8621, Japan
Nagaoka-shi, 940-2085, Japan
Naka-gun, 319-1113, Japan
Ohota-ku, 145-0063, Japan
Saiki-shi, 876-0813, Japan
Seto-shi, 489-8642, Japan
Shimotsuga-gun, 321-0293, Japan
Toon-shi, 791-0281, Japan
Yanagawa-shi, 832-0059, Japan
Warszawa Targowek, 03-291, Poland
Pytigorsk, 357538, Russia